Dec 01, 2020 7:00am EST Matinas BioPharma Appoints Hui Liu, Ph.D., M.B.A. as Chief Technology Officer
Nov 20, 2020 7:00am EST Matinas BioPharma Awarded up to $3.75 Million from the Cystic Fibrosis Foundation to Support Development of Oral Amikacin (MAT2501) for the Treatment of NTM Infections in Cystic Fibrosis Patients
Nov 19, 2020 4:15pm EST Matinas BioPharma to Participate in Annual Piper Sandler Healthcare Conference
Nov 06, 2020 7:00am EST Matinas BioPharma Reports Third Quarter 2020 Financial Results and Operational Highlights
Oct 23, 2020 7:30am EDT Matinas BioPharma to Webcast Conference Call Discussing Third Quarter 2020 Financial and Operational Results on November 6, 2020
Oct 19, 2020 6:30am EDT Matinas BioPharma Announces Unanimous DSMB Approval to Progress into Second Cohort of Patients in the EnACT Study of MAT2203 (Oral Amphotericin B) for the Treatment of Cryptococcal Meningitis
Sep 15, 2020 7:00am EDT Matinas BioPharma Announces Positive End of Phase 2 Meeting with the FDA for MAT9001 in Severe Hypertriglyceridemia (SHTG)
Sep 14, 2020 7:00am EDT Matinas BioPharma Appoints Industry Veteran Natasha Giordano to Board of Directors
Sep 10, 2020 7:00am EDT Matinas BioPharma to Participate on Anti-Fungal CEO Panel During the M-VEST Virtual Conference Series Sponsored by Maxim Group
Aug 27, 2020 4:05pm EDT Matinas BioPharma Completes Enrollment of ENHANCE-IT Study of MAT9001 Against Vascepa®
